April Chen

940 total citations
17 papers, 340 citations indexed

About

April Chen is a scholar working on Pharmacology, Molecular Medicine and Oncology. According to data from OpenAlex, April Chen has authored 17 papers receiving a total of 340 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pharmacology, 7 papers in Molecular Medicine and 4 papers in Oncology. Recurrent topics in April Chen's work include Antibiotics Pharmacokinetics and Efficacy (10 papers), Antibiotic Resistance in Bacteria (7 papers) and Pneumonia and Respiratory Infections (3 papers). April Chen is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (10 papers), Antibiotic Resistance in Bacteria (7 papers) and Pneumonia and Respiratory Infections (3 papers). April Chen collaborates with scholars based in United States, Japan and South Korea. April Chen's co-authors include Alita A. Miller, Adam B. Shapiro, Nicole Carter, Rubén Tommasi, Ning Gao, Haris Jahić, John P. O’Donnell, Sarah M. McLeod, Liyue Huang and Loren Berry and has published in prestigious journals such as Cancer Research, Journal of Medicinal Chemistry and Antimicrobial Agents and Chemotherapy.

In The Last Decade

April Chen

15 papers receiving 319 citations

Peers

Countries citing papers authored by April Chen

Since Specialization

Citations

This map shows the geographic impact of April Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by April Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites April Chen more than expected).

Fields of papers citing papers by April Chen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by April Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by April Chen. The network helps show where April Chen may publish in the future.

Co-authorship network of co-authors of April Chen

This figure shows the co-authorship network connecting the top 25 collaborators of April Chen. A scholar is included among the top collaborators of April Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with April Chen. April Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Small molecule inhibitors of mannan-binding lectin-associated serine Proteases-2 and-3 2025 ·European Journal of Medicinal Chemistry ·(unknown), (unknown), Adam B. Shapiro, Samir H. Moussa, April Chen, Charles J. Eyermann, John P. O’Donnell, Alita A. Miller, (unknown)	0
2	Hydrolysis of O-, N-, and N+-glucuronide metabolites in human feces 2025 ·Drug Metabolism and Disposition ·Zhoupeng Zhang, April Chen, Niresh Hariparsad	0
3	Fairness-Aware Graph Neural Networks: A Survey 2024 ·ACM Transactions on Knowledge Discovery from Data ·April Chen, Ryan A. Rossi, Namyong Park, (unknown), Yu Wang, Tong Yu, Sungchul Kim, Franck Dernoncourt, Nesreen K. Ahmed	6
4	Ex vivo assessment of sulbactam-durlobactam clearance during continuous renal replacement therapy to guide dosing recommendations 2024 ·Antimicrobial Agents and Chemotherapy ·Yasmeen Abouelhassan, Yuwei Shen, April Chen, Xiaoyi Ye, David P. Nicolau, Joseph L. Kuti	3
5	2526. Ex Vivo Assessment of Sulbactam-Durlobactam (SUL-DUR) Clearance during Continuous Renal Replacement Therapy (CRRT) 2023 ·Open Forum Infectious Diseases ·Yasmeen Abouelhassan, Yuwei Shen, April Chen, Xiaoyi Ye, David P. Nicolau, Joseph L. Kuti	1
6	In vivo dose response and efficacy of the β-lactamase inhibitor, durlobactam, in combination with sulbactam against the Acinetobacter baumannii-calcoaceticus complex 2023 ·Antimicrobial Agents and Chemotherapy ·John P. O’Donnell, (unknown), April Chen, Joseph Newman, Sarah M. McLeod, Rubén Tommasi	6
7	I n vitro pharmacokinetics/pharmacodynamics of the β-lactamase inhibitor, durlobactam, in combination with sulbactam against Acinetobacter baumannii-calcoaceticus complex 2023 ·Antimicrobial Agents and Chemotherapy ·John P. O’Donnell, (unknown), April Chen, Alita A. Miller, Sarah M. McLeod, Rubén Tommasi	17
8	N-Hydroxyformamide LpxC inhibitors, their in vivo efficacy in a mouse Escherichia coli infection model, and their safety in a rat hemodynamic assay 2020 ·Bioorganic & Medicinal Chemistry ·(unknown), Adam B. Shapiro, Janelle Comita-Prevoir, (unknown), Jing Zhang, Seth Ribe, April Chen, (unknown), Samir H. Moussa, Nicole Carter, Mark Sylvester, Jan Antoinette C. Romero, (unknown), M. Sacco, Yu Chen, John P. O’Donnell, Thomas F. Durand-Réville, Alita A. Miller, Rubén Tommasi	16
9	Pharmacokinetic/Pharmacodynamic Determination and Preclinical Pharmacokinetics of the β-Lactamase Inhibitor ETX1317 and Its Orally Available Prodrug ETX0282 2020 ·ACS Infectious Diseases ·John P. O’Donnell, (unknown), April Chen, (unknown), Rubén Tommasi, John P. Mueller	14
10	Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-Lactamases 2020 ·Journal of Medicinal Chemistry ·Thomas F. Durand-Réville, Janelle Comita-Prevoir, Jing Zhang, Xiaoyun Wu, Tricia L. May‐Dracka, Jan Antoinette C. Romero, Frank Wu, April Chen, Adam B. Shapiro, Nicole Carter, Sarah M. McLeod, R.A. Giacobbe, Jeroen C. Verheijen, Sushmita D. Lahiri, M. Sacco, Yu Chen, John P. O’Donnell, Alita A. Miller, John P. Mueller, Rubén Tommasi	49
11	Ceftaroline efficacy against high-MIC clinical Staphylococcus aureus isolates in an in vitro hollow-fibre infection model 2017 ·Journal of Antimicrobial Chemotherapy ·Renu Singh, Mashal M. Almutairi, Richard A. Alm, Sushmita D. Lahiri, Maryann San Martin, April Chen, Jane E. Ambler	21
12	Reversibility of Covalent, Broad-Spectrum Serine β-Lactamase Inhibition by the Diazabicyclooctenone ETX2514 2017 ·ACS Infectious Diseases ·Adam B. Shapiro, Ning Gao, Haris Jahić, Nicole Carter, April Chen, Alita A. Miller	52
13	Pharmacokinetics of the natural antibiotic negamycin 2015 ·Xenobiotica ·Jian Guo, (unknown), April Chen, (unknown), (unknown), Robert L. Walsky, Ed T. Buurman	3
14	Pharmacodynamic Profiling of a Siderophore-Conjugated Monocarbam in Pseudomonas aeruginosa: Assessing the Risk for Resistance and Attenuated Efficacy 2015 ·Antimicrobial Agents and Chemotherapy ·Aryun Kim, Amy Kutschke, David E. Ehmann, (unknown), Jared L. Crandon, (unknown), Alita A. Miller, Robert E. McLaughlin, (unknown), April Chen, Asha S. Nayar, (unknown), (unknown), Michael Rooney, Kerry E. Murphy-Benenato, Ann E. Eakin, David P. Nicolau	66
15	Use of uptake intrinsic clearance from attached rat hepatocytes to predict hepatic clearance for poorly permeable compounds 2012 ·Xenobiotica ·Liyue Huang, April Chen, John G. Roberts, (unknown), (unknown), Loren Berry, Min-Hwa Jasmine Lin	6
16	Relationship between Passive Permeability, Efflux, and Predictability of Clearance from In Vitro Metabolic Intrinsic Clearance 2009 ·Drug Metabolism and Disposition ·Liyue Huang, Loren Berry, (unknown), (unknown), April Chen, (unknown), Adria Colletti, Min-Hwa Jasmine Lin	33
17	Identification of a Novel Recepteur d'Origine Nantais/c-Met Small-Molecule Kinase Inhibitor with Antitumor Activity In vivo 2008 ·Cancer Research ·Yihong Zhang, Paula Kaplan‐Lefko, Karen Rex, Yajing Yang, Jodi Moriguchi, Tao Osgood, (unknown), Angela Coxon, (unknown), Tae‐Seong Kim, Jasmine Lin, April Chen, Teresa L. Burgess, Isabelle Dussault	47

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact